Hormonal
Non-fasting (postprandial) triglyceride levels are a significant and often neglected risk factor for premature ASCVD, as the postprandial state is the norm for most of the day and involves the accumulation of atherogenic remnant particles.
Your heart disease risk is not just determined by how you feel after an overnight fast. The hours after you eat, when fat particles are circulating, contribute significantly to plaque buildup. If you have high triglycerides, your non-fasting levels are likely even higher and more dangerous.
Population and genetic studies identify non-fasting (postprandial) hypertriglyceridaemia, occurring 8 h or more after a meal, as an important but neglected risk factor for premature ASCVD
Why this rating
Supported by population and genetic studies, though clinical protocols for characterization are lacking.
Source
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg et al. · European Heart Journal · 2021
DOI 10.1093/eurheartj/ehab551
More from this paper
- Elevated levels of triglyceride-rich lipoproteins (TRL) and their remnants are causally associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and aortic valve stenosis, independent of LDL cholesterol levels.Strong
- Apolipoprotein CIII (apoCIII) acts as a key inhibitor of lipoprotein lipase (LpL), and its reduction leads to more efficient clearance of triglycerides from the blood, thereby lowering plasma triglyceride levels and potentially reducing cardiovascular risk.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →